
Fig.1.



Primer C, includes restriction sites 3 and 4

Primer D, includes restriction sites 3 and 4




Fig.2.

aroC

AAACACAACAATAACGGAGCGTGATG...TAAAAATGAATAAAACCGCGATTG CG deletion ¥.

AAACACAACAATAACGGAGCCCTCGAGGCATGCTGAATAAAATGAATAAAACCGCGATTG CG

→

TGTTAATCGAGAXTGAAATACATGAA---AGTAATCTCCCTCAACCCCTTCCT GAA TGTTAATCGAGAXTGAAATACCTCGAGTCTAGACTCCCTCAACCCCTTCCT GAA deletion

ompC

ATATAACAGAGGGTTAATAACATGAAA---CAGTTCTAA TCTCGATTGATATCGAAC ATATAACAGAGGTTAATAACGCCTAAGCCTCGAGTAA TCTCGATTGATATCGAAC deletion

ompF

AAACCATGAGGGTAATAAAATAgaGC7AAGCC7CGAGCAGTTC<mark>TAA</mark> TAGCACACCTCTTTGTTA AAACCATGAGGGTAATAAAATAATGATGAAGCGC---CCAGTTCTAA TAGCACACCTCTTTGTTA deletion

ompR

CGAACCTTTGGGAGTACAAACAATGCAA---AAGCATGA GGCGATTGCGCTTCTCGCCA CGAACCTTTGGGAGTACAAACAGCGCATGCGAGGGGGATTGCGCTTCTCGCCA deletion

Bold - Stop and start codons


Italics - restriction enzyme sites introduced

Underlined – primer binding sites

Lower case – extra n.t added to primers to avoid primer dimer formation

--- wild type gene

N.B. aroC deletion removes 16 n.t. 3' to the stop codon



DOSTEGES OF SEC

Fig.4.






Fig.5.



Anti-CS3 antibody



SUBSTITUTE SHEET (RULE 26)




Fig.7. PBMNC IgA Responses 5x10⁹ cfu Dose 1.8-1.6 1.4 1.2 • Day 0 • Day 7 0 □Day 10 0.0 Day 0 Day 7 Day 10